This PhD project focused on investigating the structure-activity relationships (SARs) of the ribbon isomer of a-conotoxins, providing the basis for using a-conotoxin ribbon isomers as scaffolds in drug design to target nicotinic acetylcholine receptors (nAChRs). Chaptern1 provides an introduction to the structure and function of nAChRs and to a-conotoxins, as well as introducing the concept of disulfide isomers of a-conotoxins. Chapters 2 to 5 describe the engineering of ribbon isomers of a-conotoxins for drug design application, as summarised below.Chapter 2 describes a strategy to improve the yield of synthesis of a ribbon conotoxin, enabling the creation of mutants for SAR studies. The three-disulfide isomers of aO-conotoxin GeXIVA, i.e. the globular, ribbon and beads isomers, have similar potency at the a9a10 nAChR, which is considered to be a pain target. Owing to its potent activity, GeXIVA prompts further studies to investigate its analgesic potential. Unfortunately, the directed folding using orthogonal protection of cysteine residues is difficult for GeXIVA because it has a long sequence and has poor assembly yields arising from numerous Arg residues. Chapter 2 of this thesis shows that the folding of the ribbon GeXIVA could be achieved directly using rationally designed backbone cyclising linkers instead of using an orthogonal protection strategy. Additionally, backbone cyclisation of the ribbon GeXIVA was shown to improve peptide stability in human serum and have comparable activity as the parent peptide.Chapter 3 focuses on the determination of the binding mode of an a-conotoxin, AuIB, which is an essential step for structure-based design of ribbon a-conotoxins. The ribbon isomer of a-conotoxin AuIB has 10-fold higher potency than the wild-type globular isomer at inhibiting nAChRs in rat parasympathetic neurons, and unlike its globular isoform, ribbon AuIB targets a specific stoichiometry of the a3b4 nAChR subtype. This specificity for a particular stoichiometry is remarkable and suggests that the ribbon isoform of a-conotoxins has potential applications in drug design. In Chapter 3, the binding mode and SAR of ribbon AuIB were investigated to determine the features that underpin its specific activity using a combination of molecular modelling and electrophysiology recording. An alanine scan showed that positions 4 and 9 of ribbon AuIB are the main determinants of the interactions with rat (a3)3(b4)2 nAChR. Computational models indicated that the first loop of ribbon AuIB bound in the laromatic boxr of the acetylcholine orthosteric binding site. In contrast, the second loop and the termini of the ribbon isomer had different orientations and interactions in the binding sites than those of the globular isomer.In Chapter 4, several computation methods for predicting mutational energies of a-conotoxins were compared, and the optimal method could be used for rational computational design. Binding free energy predictions are potentially an important tool for designing selective inhibitors based on globular and ribbon a-conotoxins but these computational methods need to be benchmarked to assess their accuracy in the context of nAChR/conotoxin systems. Computational free energy predictions are especially sensitive to the accuracy of the structural models; ultimately they should be used with high-resolution experimental structures. Unfortunately, there is so far no crystal structure of nAChR in complex with a-conotoxin. By contrast, the acetylcholine binding proteins (AChBPs), which are structurally homologous to the extracellular domains (ECDs) of the nAChRs, can be relatively easily crystallised and studied using X-ray crystallography. The crystal structures of AChBP/a-conotoxin complexes provide important information on the binding mode of the a-conotoxin. In Chapter 4, we evaluated four mutational energy prediction methods (BeAtMuSic, Foldx, MMPBSA/MMGBSA, and coarse-grained umbrella sampling) using the crystal structure of the complex between AChBP and a-conotoxin LsIA and between AChBP and LvIA, and associated experimental affinity change of these complexes after mutations. Foldx was identified as the most reliable method for mutational energy prediction. Notably, this method was successful at predicting variations with increased or decreased affinities.Chapter 5 combined results from the two previous chapters to the study of the binding mode of the a-conotoxin GID with the a4b2 nAChR. The a4b2 nAChR is linked to a range of diseases and disorders including nicotine addiction, epilepsy, and Parkinsonrs and Alzheimerrs diseases. Designing a4b2 nAChR selective inhibitors could help refine the role of a4b2 nAChR in disease states. In Chapter 5, we aimed to modify globular and ribbon a-conotoxin GID to selectively target the a4b2 nAChR through competitive inhibition of the a4(+)b2(-) or a4(+)a4(-) interfaces. The binding modes of the globular a-conotoxin [Gla4E]GID with rat a3b2, a4b2 and a7 nAChRs were built using computational methods, and they were validated using published experimental data. The binding mode of globular [Gla4E]GID at a4b2 nAChR can rationally explain the experimental mutagenesis data, suggesting that it could be used to design GID variants rationally. The predicted mutational energy results showed that globular [Gla4E]GID seemed to be already optimal for binding to a4b2 nAChR and its activity cannot further be improved through amino-acid substitutions. The cryo-electron microscopy structure of (a4)3(b2)2 nAChR has been recently released, providing an optimal template to build the binding mode of the ribbon GID with (a4)3(b2)2 nAChR using information on the binding mode of ribbon AuIB studied in Chapter 3. The Foldx predicted the mutational energies of ribbon [Gla4E]GID at a4(+)a4(-) interface, and a number of ribbon [Gla4E]GID mutants were suggested to have desirable properties to inhibit (a4)3(b2)2 nAChR.Chapter 6 provides an overview of my findings and highlights the major conclusions of the thesis, as well as suggesting ideas for future studies in this field. In summary, my PhD thesis has shown that ribbon a-conotoxins can be used in the design of specific nAChR inhibitors.